Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

Benny Sorensen appointed Chief Executive Officer and Co-Founder Johan Henrik Faber appointed Chief Technology Officer Financing led by Novo Holdings, HealthCap and RA Capital Management Advancing pipeline of bispecific and monoclonal antibodies with ... Biopharmaceuticals, Venture Capital Hemab , thrombosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news